Comprehensive genetic analyses of relapsed B-cell precursor acute lymphoblastic leukemia in children

DOI IR HANDLE Web Site
  • Kubo Kaori
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Kudo Ko
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Toki Tsutomu
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Kanezaki Rika
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Ikeda Fumika
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Ito Tatsuya
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Kobayashi Akie
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Sato Tomohiko
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Kamio Takuya
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Sasaki Shinya
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Terui Kiminori
    Department of Pediatrics, Hirosaki University Graduate School of Medicine
  • Ito Etsuro
    Department of Pediatrics, Hirosaki University Graduate School of Medicine

Search this article

Abstract

The causes for individual relapse in children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remain incompletely understood. Here, we performed comprehensive genetic analyses of 20 pediatric BCP-ALL paired diagnosis-relapse samples. Copy number variation analysis of IKZF1, a gene for which deletions are associated with increased relapse risk, revealed deletions at both diagnosis and at relapse (n=5). Targeted next generation sequencing showed that RAS pathway genes including KRAS (n=4), NRAS (n=2) and PTPN11 (n=2) were the most common mutations among the sequencing targets at diagnosis and/or relapse. In 7 of 20 cases (35%), mutations in PTPN11, KRAS, TP53, CTCF, NCOR1, WHSC1, TUSC3, ERG and NT5C2   were detected only at relapse. Two cases with TP53   mutations showed fatal outcomes. In two of the four cases with high hyperdiploid BCP-ALL, associated with favorable prognosis, PTPN11 mutations were detected only at relapse. Targeted RNA sequencing identified a rare subtype of BCP-ALL with a NUP214-ABL1 fusion that could benefit from tyrosine kinase inhibitors. Together with recent reports that RAS mutations confer sensitivity to MEK inhibitors, these results suggest that comprehensive genetic analysis will contribute to the optimal treatment for relapsed BCP-ALL.

Journal

  • Hirosaki Medical Journal

    Hirosaki Medical Journal 70 (1), 13-23, 2019

    Hirosaki University Graduate School of Medicine,Hirosaki Medical Society

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top